Revita starts multi-modality clinical intervention for brain dead patients

New Delhi: Revita Life Sciences, a biotechnology company focused on translational regenerative therapeutic applications, has announced that it has started the novel, multi-modality clinical intervention for brain-dead patients on compassionate grounds in New Delhi.

"We are confident that our small steps with our multi-modality protocol to reverse the state of brain death like this will change the outcome in these subjects in near future. Bioquark USA is a valuable scientific collaborator in this project," said Pranjal Agrawal, CEO, Revita Life Sciences. Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through

Death is defined as the termination of all biological functions that sustain a living organism. Brain death, the complete and irreversible loss of brain function (including involuntary activity necessary to sustain life) as defined in the 1968 report of the Ad Hoc Committee of the Harvard Medical School, is the legal definition of human death in most countries around the world. Either directly through

Either directly through trauma or indirectly through secondary disease indications, brain death is the final pathological state that over 60 million people globally transfer through each year. "The fact that more institutions are accepting and coming on-line with our exploratory protocol highlights a very promising dynamic in the quest to reverse the most severe disorder of consciousness," said Dr. Himanshu Bansal, Chief Scientific Officer, Revita Life Sciences and Director of Mother Cell. "Moving to such a multi-centered model will prove invaluable to the future evolution of the program, as well as in progressing the development of multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans," he said.

"Moving to such a multi-centered model will prove invaluable to the future evolution of the program, as well as in progressing the development of multi-modality regenerative therapeutics for the full range of the severe disorders of consciousness, including coma, PVS, the minimally conscious state, and a range of other degenerative CNS conditions in humans," he said. Dr S K Tiwari expert in regenerative medicine said that such translational work gives more insight to CNS regeneration.

With the maturation of the tools of medical science in the 21st century, especially cell therapies and regenerative medicines, tissues once considered irretrievable may finally be revived or rejuvenated. Hence, many scientists believe that brain death, as presently defined, may one day be reversed. While the very long-term goal is to find a solution for 're-infusing life', the short-term purpose of these studies is much less dramatic, which is to confirm if the current definition of brain irreversibility still holds true.

There have been many anecdotal reports of brain death reversal across the world over the past decades in the scientific literature. Studies of this nature serve to verify and establish this very fact in a scientific and controlled manner. It will also one day give a fair chance to individuals, who are declared brain dead, especially after trauma.